Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 3
1980 1
1981 4
1982 4
1983 3
1984 4
1985 3
1986 8
1987 4
1988 6
1989 11
1990 13
1991 8
1992 18
1993 25
1994 28
1995 8
1996 27
1997 14
1998 18
1999 18
2000 15
2001 12
2002 20
2003 23
2004 18
2005 22
2006 20
2007 22
2008 10
2009 13
2010 14
2011 13
2012 8
2013 10
2014 8
2015 8
2016 14
2017 10
2018 6
2019 6
2020 7
2021 4
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

489 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. Among authors: krenning e. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Pavel M, et al. Among authors: krenning ep. Ann Oncol. 2020 Jul;31(7):844-860. doi: 10.1016/j.annonc.2020.03.304. Epub 2020 Apr 6. Ann Oncol. 2020. PMID: 32272208 Free article. No abstract available.
ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas).
Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, Krenning E, Reed N, O'Toole D; Vienna Consensus Conference participants. Pape UF, et al. Among authors: krenning e. Neuroendocrinology. 2016;103(2):144-52. doi: 10.1159/000443165. Epub 2016 Jan 5. Neuroendocrinology. 2016. PMID: 26730583 Free article. No abstract available.
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. Strosberg JR, et al. Among authors: krenning ep. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. Lancet Oncol. 2021. PMID: 34793718 Clinical Trial.
ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum.
Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, O'Toole D, Krenning E, Reed N, Kianmanesh R; Vienna Consensus Conference participants. Niederle B, et al. Among authors: krenning e. Neuroendocrinology. 2016;103(2):125-38. doi: 10.1159/000443170. Epub 2016 Jan 12. Neuroendocrinology. 2016. PMID: 26758972 Free article. No abstract available.
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site.
Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Öberg K; Vienna Consensus Conference participants. Pavel M, et al. Among authors: krenning e. Neuroendocrinology. 2016;103(2):172-85. doi: 10.1159/000443167. Epub 2016 Jan 5. Neuroendocrinology. 2016. PMID: 26731013 No abstract available.
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.
Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ. Brabander T, et al. Among authors: krenning ep. Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. doi: 10.1158/1078-0432.CCR-16-2743. Epub 2017 Apr 20. Clin Cancer Res. 2017. PMID: 28428192
Somatostatin receptor imaging.
Kwekkeboom DJ, Krenning EP. Kwekkeboom DJ, et al. Among authors: krenning ep. Semin Nucl Med. 2002 Apr;32(2):84-91. doi: 10.1053/snuc.2002.31022. Semin Nucl Med. 2002. PMID: 11965603 Review.
Octreoscan radioreceptor imaging.
van der Lely AJ, de Herder WW, Krenning EP, Kwekkeboom DJ. van der Lely AJ, et al. Among authors: krenning ep. Endocrine. 2003 Apr;20(3):307-11. doi: 10.1385/ENDO:20:3:307. Endocrine. 2003. PMID: 12721512 Review.
Gastroenteropancreatic neuroendocrine tumours.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Modlin IM, et al. Among authors: krenning ep. Lancet Oncol. 2008 Jan;9(1):61-72. doi: 10.1016/S1470-2045(07)70410-2. Lancet Oncol. 2008. PMID: 18177818 Review.
489 results